0001104659-21-023428.txt : 20210216 0001104659-21-023428.hdr.sgml : 20210216 20210216120748 ACCESSION NUMBER: 0001104659-21-023428 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210212 FILED AS OF DATE: 20210216 DATE AS OF CHANGE: 20210216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Oren Dan CENTRAL INDEX KEY: 0001636701 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33357 FILM NUMBER: 21634766 MAIL ADDRESS: STREET 1: 1 DEXCEL STREET CITY: OR AKIVA STATE: L3 ZIP: 30600000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dexcel Pharma Technologies Ltd. CENTRAL INDEX KEY: 0001720007 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33357 FILM NUMBER: 21634767 BUSINESS ADDRESS: STREET 1: 1 DEXCEL STREET CITY: OR AKIVA STATE: L3 ZIP: 3060000 BUSINESS PHONE: 97246364040 MAIL ADDRESS: STREET 1: 1 DEXCEL STREET CITY: OR AKIVA STATE: L3 ZIP: 3060000 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001006281 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 650643773 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 2161401 BUSINESS PHONE: 972-4-988-9488 MAIL ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 2161401 FORMER COMPANY: FORMER CONFORMED NAME: ORTHODONTIX INC DATE OF NAME CHANGE: 19980422 FORMER COMPANY: FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP DATE OF NAME CHANGE: 19960124 3 1 tm216121d3_3.xml OWNERSHIP DOCUMENT X0206 3 2021-02-12 0 0001006281 Protalix BioTherapeutics, Inc. PLX 0001720007 Dexcel Pharma Technologies Ltd. 10 HAKIDMA STREET YOKNEAM L3 2069200 ISRAEL 0 0 1 0 0001636701 Oren Dan 1 DEXCEL STREET OR AKIVA L3 3060000 ISRAEL 0 0 1 0 Common Stock 4556031 D Common Stock Purchase Warrants 2.36 2020-03-11 2025-03-11 Common Stock 2816901 D The warrants contain a blocker that prohibits the holder from exercising the warrants if such exercise will result in beneficial ownership of more the 9.99% of the Issuer's outstanding common shares by the warrantholder and its affiliates. Since the reporting persons' beneficial ownership percentage is over 9.99%, the warrants are currently not exercisable. /s/ Dexcel Pharma Technologies Ltd. by Dan Oren, Executive Chairman 2021-02-16 /s/ Dan Oren 2021-02-16